Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|March 26, 2025

Addressing Data and Patient Retention Challenges

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, highlights how addressing these challenges can aid industry in moving more towards the future.

In a recent video interview with Applied Clinical Trials, Rachael Higgins, chief commercial officer, PicnicHealth, discussed the company’s recently released 2025 Annual State of Observational Research Report. She highlighted some of the key findings including the persistence of more traditional research methods as well as how patient retention and incomplete data are creating challenges for the industry.

ACT: How can industry address some of the challenges holding it back from moving towards the future such as incomplete data and patient retention?

Higgins: I think for companies, the life science partners that we do have, I think they truly need to not only say that they're open to things like virtual trials, but actually to be able to embrace them and actually take that leap to be able to do more of that, because that really is the only way to truly do things like getting access to the universal patient record by having patients consent directly, allowing you to get access to their medical record. It is a way that's no burden, or less burden to the patient, and then also give something back to the patient. Things like allowing patients to get access to their medical records and to be able to share their medical records, to be involved in the research, things like that are really going to certainly help them be able to scale up in the ways that they need to be able to do. When you think about all of our customers who are out there and the challenges that they have, I think they're all solvable. I think it's just getting them comfortable in the fact that the old way doesn't have to be the only way, right? There are certainly many ways to skin a cat, and I think these new ways certainly have proven to be effective. I think, again, it's just taking that leap. And then certainly, when you think about where the future is actually going to, the R&D costs are rising tremendously year over year. You see it in the news constantly with our life science partners having to make very significant cuts with not only their staff, thinking about their pipeline, what it is they're going to do, so they have to do more with less, and again, leveraging some of these types of models, virtual opportunities, leveraging direct connection to the patients, leveraging AI, that's going to be able to address their problems, which is going to allow them to scale in the future, which is really what everybody wants, which, again, at the end of the day, is going to be able to bring medicines to patients, which is really what we all want.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.